Form 4: Phio Pharma Grants VP 47,000 Restricted Stock Units

Phio Pharmaceuticals Corp. granted its VP of Finance and Administration, Lisa Cabott Carson, 47,000 restricted stock units vesting in one year.

Summary

• Lisa Cabott Carson, VP, Finance and Administration of Phio Pharmaceuticals Corp. (PHIO), acquired 47,000 shares of common stock.
• These shares represent restricted stock units (RSUs) granted on September 11, 2025.
• The RSUs will vest on the first annual anniversary of the grant date.
• The transaction price for the grant was $0, which is typical for equity compensation awards.
• Following this transaction, Carson beneficially owns 47,000 shares, which include these unvested restricted stock units.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a key executive is a positive for aligning management incentives with shareholder interests and executive retention, though it is a routine compensation event rather than a significant operational or financial announcement.

Positives

• The grant of 47,000 restricted stock units to a key executive, Lisa Cabott Carson, aligns management incentives with shareholder interests.
• The vesting schedule encourages long-term commitment and performance from the VP, Finance and Administration.

Future Outlook

The restricted stock units granted on September 11, 2025, are scheduled to vest on their first annual anniversary, indicating future beneficial ownership for the reporting person.

Management Comments

• Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant.
• Includes shares of common stock underlying unvested restricted stock units.

Industry Context

The grant of restricted stock units is a standard practice in the biotechnology and pharmaceutical industries for executive compensation, aiming to retain key talent and align their interests with long-term company performance.

Comparison to Industry Standards

• The use of restricted stock units for executive compensation is a common practice across the biotech and pharmaceutical sectors, comparable to compensation structures observed in companies like Moderna, BioNTech, or Regeneron, which frequently utilize equity awards to incentivize leadership.

Stakeholder Impact

• Shareholders: Aligns the interests of a key executive with long-term shareholder value through equity ownership.
• Employees (Lisa Cabott Carson): Provides significant equity compensation, incentivizing retention and performance.

Next Steps

• The 47,000 restricted stock units granted on September 11, 2025, will vest on the first annual anniversary of that grant date.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the grant of restricted stock units. While positive for executive alignment, it does not provide new information that would fundamentally alter the investment thesis for Phio Pharmaceuticals Corp., thus a 'hold' recommendation remains appropriate based solely on this filing.

Keywords

Phio Pharmaceuticals, PHIO, restricted stock units, RSU, executive compensation, insider transaction, Form 4, Lisa Cabott Carson